For individuals battling Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a debilitating condition, the arrival of this treatment and Tafamidis meglumine represents a true change. These groundbreaking therapies protect the transthyretin protein, preventing its destructive build-up and alleviating the burden of the condition . People are now reportin